Navigation Links
David Mott Appointed Non Executive Director at Shire
Date:10/31/2007

BASINGSTOKE, England, October 31 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces today that David Mott will join the Board as a Non Executive Director with immediate effect.

Mr Mott is Chief Executive Officer and President of MedImmune, Inc, a role he was appointed to in 2000. He joined MedImmune in 1992 and has held positions of increasing responsibility in finance, strategic planning, business development, medical and regulatory including the positions of Chief Financial Officer and Chief Operating Officer. MedImmune was acquired by AstraZeneca (AZ) in June 2007, and Mr. Mott is also now serving as Executive Vice President of AZ and a member of AZ's Senior Executive Team.

Prior to joining MedImmune, Mr Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co., Inc.

Mr Mott is a member of the Board of Directors of Rib-X Pharmaceuticals and also serves on the Boards of Directors of the Biotechnology Industry Organization (BIO) and the Technology Council of Maryland and MdBio. He holds a bachelor's degree in economics and government from Dartmouth College, New Hampshire, USA.

Dr James Cavanaugh, Chairman of Shire commented:

"David's experience in the pharmaceutical industry, particularly in biotechnology is a welcome addition to our Board. As we reinforce Shire's status as a growing global biopharmaceutical company, we will benefit greatly from David's insight and talents."

David Mott added:

"Shire is one of the most interesting companies in the industry with an impressive recent track record of launches and an equally exciting pipeline. I'm very pleased to be joining the Shire team at this point in the Company's development."

There are no details that are required to be disclosed under paragraph 9.6.13( 1-6) of the Listing Rules of the Financial Services Authority.

Notes to Editors

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGF beta 3) and GA-GCB (velaglucerase alfa); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.


'/>"/>
SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. David Brooks: Segmented nation looks for solidarity amid IT-powered niches
3. CIO Leadership Series: Rick Davidson, Manpower
4. CIO Leadership Series: David Melbye, Milwaukee Metro Sewerage District
5. CIO Leadership Series: David Cagigal, Alliant Energy
6. VanderSanden appointed president of AT&T Wisconsin
7. Chemical-petroleum executive joins Virent Energy board
8. Visions: Matheys says CIO role is good training for executive suite
9. Biotech executive books a career flight thats closer to home
10. CEOs Gone Wild? Risks and rewards in the executive suite
11. Early-stage executives hear from investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 According to ... products and derivatives market is fragmented due to the presence of a ... as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each ... three companies, collectively, held more than 76% of this market in ... As of ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Genetics Center (RGC), U.K. Biobank and GSK to generate genetic ... Biobank resource. The initiative will enable researchers to gain valuable ... for a wide range of serious and life threatening diseases. ... Genetic ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):